Arrowhead Pharmaceuticals Presents Phase 3 Shasta-3 And Shasta-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events In Patients With Severe Hypertriglyceridemia
ARWR•Source and reporting note
Source text: ID:nBw8Xh7XGa
Further company coverage: ARWR.O
(Reporting by Gargi Gupta)
Phase 3 data on plozasiran
Aug. 30 (Reuters) - Arrowhead Pharmaceuticals, Inc. ARWR.O:
- Arrowhead Pharmaceuticals presents phase 3 Shasta-3 and Shasta-4 data demonstrating plozasiran reduced acute pancreatitis events in patients with severe hypertriglyceridemia
- Arrowhead Pharmaceuticals - to file supplemental NDA with U.S. FDA by year-end 2026 using priority review voucher
- Arrowhead Pharmaceuticals - plozasiran demonstrated favorable safety and tolerability profile in phase 3 studies
